Welcome to our dedicated page for Anavex Life Scie news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Scie stock.
Anavex Life Sciences Corp. reports developments as a clinical-stage biopharmaceutical company focused on central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other neurodevelopmental, neurodegenerative, and rare diseases. Company news frequently centers on blarcamesine, its orally administered lead candidate, along with precision-medicine analyses using genomic and biomarker data.
Recurring updates include clinical and preclinical data presentations, scientific findings related to autophagy, synaptic dysfunction, SIGMAR1 biology, and disease mechanisms, as well as regulatory communications with the FDA and EMA. News also covers financial results, healthcare conference participation, board composition, executive leadership changes, and other corporate governance matters.
Anavex Life Sciences (Nasdaq: AVXL) appointed Terrie Kellmeyer, PhD, as interim CEO effective May 6, 2026, following the departure of prior CEO Christopher Missling on April 30, 2026 and a request for his board resignation. Dr. Kellmeyer will prioritize clinical, regulatory and operational strategy for the company’s CNS pipeline, including lead candidate oral blarcamesine. The company said it has a strong cash balance with no long-term debt and expects to file a Form 12b-25 to extend its Form 10-Q filing for the quarter ended March 31, 2026. A conference call and webcast will be scheduled with further details.
Anavex (Nasdaq: AVXL) reported new scientific findings linking autophagy dysfunction and synaptic pruning deficits in autism spectrum disorder (ASD) with mechanisms in Alzheimer’s disease (AD). These data reinforce the biological rationale for orally administered blarcamesine, a SIGMAR1 activator, and support advancing blarcamesine into pivotal clinical studies subject to further evaluation and regulatory review.
Clinical evidence cited includes Phase IIb/III AD results, Phase II/III Rett syndrome signals, and Phase II Parkinson’s disease dementia proof-of-concept.
Anavex Life Sciences (Nasdaq: AVXL) will present at the 25th Annual Needham Virtual Healthcare Conference April 13–16, 2026. Management is scheduled to present on Tuesday, April 14, 2026 at 1:30 PM ET. A live audio webcast and same‑day archived edition will be available via the company website.
Anavex Life Sciences (Nasdaq: AVXL) provided a regulatory update on March 30, 2026: the company withdrew its EU marketing authorization application for oral blarcamesine in early Alzheimer’s disease and will gather additional data while continuing dialogue with the EMA and CHMP.
Anavex also submitted additional data to the U.S. FDA to discuss potential pathways toward an NDA for early Alzheimer’s disease and is engaging EU regulators for blarcamesine in Parkinson’s disease and rare disorders including Rett syndrome.
Anavex (Nasdaq: AVXL) withdrew its EU marketing authorization application for blarcamesine as an add-on therapy for early Alzheimer’s disease on March 25, 2026 after the EMA’s CHMP indicated it would not be in a position to issue a positive opinion.
The company said it will consider CHMP feedback, gather additional data, conduct further analyses, and continue clinical development while maintaining engagement with regulators and patient organizations.
Anavex Life Sciences (Nasdaq: AVXL) presented new AD-004 Phase IIb/III data at AD/PD 2026 showing a consistent correlation between oral blarcamesine’s treatment effect and preservation of brain volume in early Alzheimer’s disease.
Key metrics: 77.4 weeks saved versus ADNI1 after 144 weeks of treatment and a 78% R² increase for ADAS-Cog13 in the ABCLEAR32 genomic subgroup (R² 0.23 to 0.41).
The company emphasized oral dosing convenience, MRI–clinical endpoint coherence, and a precision‑medicine signal in SIGMAR1/COL24A1 wild‑type patients; results remain investigational with no guarantee of approval.
Anavex (Nasdaq: AVXL) highlighted a March 20, 2026 peer‑reviewed PNAS publication proposing that autophagy failure precedes amyloid beta and tau pathology in Alzheimer’s disease. The study links impaired neuronal autophagy to intracellular Aβ accumulation and microtubule/tau disruption, aligning with Anavex’s blarcamesine SIGMAR1 mechanism that aims to restore autophagy.
The company said this research reinforces the rationale for targeting upstream autophagy dysfunction as a potential disease‑modifying approach, while noting investigational uses are not proof of safety or efficacy.
Anavex (Nasdaq: AVXL)/b) reported new preclinical data showing and produced a dopaminergic nerve fiber regrowth biomarker in striatum after six weeks in a new dual‑hit Parkinson’s disease model.
The model combines alpha‑synuclein accumulation and noradrenergic degeneration; results were presented at AD/PD 2026 and the company continues advancing clinical development for early Parkinson’s disease.
Anavex Life Sciences (Nasdaq: AVXL) will present at the Citizens Life Sciences Conference. Christopher U Missling, PhD, President & CEO, is scheduled to speak on Tuesday, March 10, 2026 at 11:55 AM ET.
The presentation covers company developments in clinical-stage CNS programs including Alzheimer’s, Parkinson’s, schizophrenia, Rett syndrome and other neurodegenerative and rare diseases.
Anavex Life Sciences (Nasdaq: AVXL) announced that President & CEO Christopher U Missling, PhD will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 11:50 AM ET.
A live audio webcast will be available via the company’s Investors section at www.anavex.com, and an archived edition will be posted later that day.